SuperGen Inc., of Dublin, Calif., was issued U.S. Patent No. 6,319,943 covering the company’s oral formulation of paclitaxel, which includes pharmaceutically acceptable, water miscible solubilizers other than Cremophor, which are believed to have improved long-term stability and reduced adverse effects relative to existing formulations.

Therion Biologics Corp., of Cambridge, Mass., said it obtained licenses from the U.S. Public Health Service giving it exclusive worldwide rights under 21 patents and patent applications related to immunotherapy and cancer vaccine development. The intellectual property covers technologies, methods of use, and specific vaccines developed in conjunction with the company’s two Cooperative Research and Development Agreements with the National Cancer Institute.

No Comments